Gastro Esophageal Reflux Clinical Trial
Official title:
Initiation of Acid Suppression Therapy Prospective Outcomes for Laryngomalacia
Laryngomalacia (LM) is the most common cause of stridor in infants. Symptoms of gastroesophageal reflux (GER) are often seen in the setting of LM; therefore, acid suppression therapy (AST) has been empirically used in the management of this disorder. The investigators recently performed a retrospective chart review assessing improvement of airway and dysphagia symptoms, weight gain, and need for surgery with AST. It was found that there was a similar improvement between LM severity groups and most patients received AST (96.6%). It is unclear if these improvements are due to AST or natural resolution of the disease. With heightened concerns of side effects related to AST in infants, particularly among those born prematurely, judicious use of these medications is needed. The investigators are now performing a prospective study looking at the outcome differences in patients with laryngomalacia who are evaluated by speech language therapy (SLP) alone versus those with SLP evaluation and acid suppression therapy (famotidine).
Purpose: To determine the outcome differences in patients 6 months and younger with laryngomalacia and dysphagia who are evaluated by speech language therapy (SLP) alone versus those with both SLP evaluation and acid suppression therapy (AST) (famotidine) Hypothesis: There will be no differences in outcomes between those that had SLP alone versus those that had both SLP and AST. Laryngomalacia (LM) is the most common cause of stridor in infants. Symptoms of gastroesophageal reflux (GER) are often seen in the setting of LM; therefore, acid suppression therapy (AST) has been empirically used in the management of this disorder. However, there is no gold standard in treating mild and moderate LM patients and therefore this study will help establish guidelines for treatment. A medical chart review will be performed to assess airway and dysphagia symptom improvement from consult to the 3-month follow up appointment and then up to a year. The Pittsburgh Airway Symptom Score (PASS) questionnaire and the Infant Gastroesophageal Reflux Questionnaire (I-GERQ-R) will be given to families at the consult and at the 3-month follow up appointment for caregiver assessment. The physician will then perform the standard procedures at the clinic appointment. The Flexible Laryngoscopy Findings sheet will be filled out in conjunction with the clinic procedures for objective data. The surveys will then be scored to determine true GERD (score >=16) and severe laryngomalacia (LM) (RED questions on the PASS), which would further exclude these patients. There are 12 total questions on the I-GERQ-R. On the PASS, questions 1 & 2 are in the GREEN category and signifies mild LM, YELLOW signifies moderate LM, and RED is severe LM. On the PASS questionnaire, "Yes" to either #1 or #2 and nothing else is mild LM, "yes" to at least one #3-5 and none of #6-10 is moderate LM, and "yes" to any of the #6-10" indicates severe LM. There are 10 total questions on the PASS. Mild and moderate LM patients will be block randomized the day before the appointment to receive speech language therapy alone or speech language therapy with famotidine (Pepcid). Both treatments are standard of care in these patients. Speech language therapy (feeding therapy) is part of the normal clinic visit for LM patients. These patients will then be re-evaluated at their follow up appointment in 3 months (+/- 1 month). The families will take the PASS and I-GERQ-R surveys again to determine LM severity. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06025773 -
A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-212-A and AD-2121
|
Phase 1 | |
Recruiting |
NCT06280664 -
Efficacy Of Hiatal Closure For GERD
|
||
Recruiting |
NCT05359965 -
Effect of CPAP on Abnormal Gastroesophageal Reflux and Lung Inflammation in IPF
|
N/A | |
Completed |
NCT04202692 -
Effect of a Combination Oral Formulation of Hyaluronic Acid, Chondroitin Sulphate and Magnesium Trisilicate in Patients With Gastro-Esophageal Reflux Disease Not Fully Satisfied With Their Treatment
|
N/A | |
Active, not recruiting |
NCT03646045 -
Transpyloric Feeding for Prevention of Micro-aspiration
|
||
Recruiting |
NCT06430047 -
Efficacy and Safety of EsoDuo®
|
Phase 4 | |
Completed |
NCT04268719 -
Near Focus NBI-Driven Artificial Intelligence for the Diagnosis of Gastro-Oesophageal Reflux Disease
|
||
Terminated |
NCT05579444 -
Systems Biology of Gastrointestinal and Related Diseases
|
||
Recruiting |
NCT03868267 -
Japanese Upper GI Symptoms Compared With Iranian and Canadian Patients Presenting
|
||
Terminated |
NCT04028466 -
Effectiveness of Vonoprazan vs Omeprazole as Empiric Therapy for Gastroesophageal Reflux Disease (GERD) Patients Without Alarm Features
|
Phase 4 | |
Active, not recruiting |
NCT05371717 -
Domiciliary Management of Dental Erosion in Patients With GERD With Biomimetic Hydroxyapatite
|
N/A | |
Recruiting |
NCT05066594 -
Observational Registry of Transoral Incisionless Fundoplication (TIF) for Gastroesophageal Reflux Disease (GERD)
|
||
Completed |
NCT03476265 -
Lower Esophageal Sphincter (LES) Stimulation in Patients With Ineffective Esophageal Motility
|
N/A | |
Completed |
NCT03143608 -
GERD Treatment With Transoral Incisionless Fundoplication (TIF) Following Hiatal Hernia Surgery
|
N/A | |
Completed |
NCT04436159 -
Partial Versus Total Fundoplication in the Surgical Repair of Para-esophageal Hernia.
|
N/A | |
Completed |
NCT03258528 -
Effect of Right Lateral Position on Ventilated Preterm Neonates
|
N/A | |
Active, not recruiting |
NCT04500288 -
The Effect of Positional Therapy on Symptoms of Gastroesophageal Reflux Disease: A Prospective Pilot Study
|
N/A | |
Completed |
NCT04262648 -
Randomized Placebo-controlled Study of L. Reuteri NCIMB 30351 in GI Functional Disorders and Food Allergy in Newborns
|
N/A | |
Recruiting |
NCT04846010 -
Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03835663 -
The Bacterial Composition of the Stomach in Reflux Disease
|